Fetal Origin of Adult Diseases Clinical Trial
Official title:
Maternal Transcriptomic Regulation of the Preimplantation Embryo
The aim of this study is to understand the epigenetic and transcriptomic mechanisms that
regulate the fetal origin of adult diseases (FOAD), either for the presence of metabolic
disorders in the future mothers, such as obesity or for the exposure to certain contaminants
such as tobacco.
To do that, the miRNAs profiles secreted to the endometrial fluid in obese women vs
normoweight women during the window of implantation will be identified. Likewise, it will be
studied how that miRNA signature is normalized once a substantial loss of weight is produced
by the patients involved in the studied. In parallel, a comparison of the miRNA expression
profiles secreted in the endometrial fluid in smoker women vs nonsmoker women will be
performed. As in the previous case, it will be studied if after the exposure to these
contaminant, the normalization of the miRNA expression signature occurs. Finally, an in
silico analysis will be carried out in order to define the target genes and the metabolic
pathways affected by the miRNAs profile secreted in both pathological conditions
| Status | Recruiting |
| Enrollment | 90 |
| Est. completion date | April 2019 |
| Est. primary completion date | April 2017 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Female |
| Age group | 18 Years to 45 Years |
| Eligibility |
Inclusion Criteria: - Women with age comprised between 18 and 45 years - Normal uterus (evaluated trough ultrasound 2D/3D and/or hysteroscopy) - Presence of at least one ovary - Body mass index: - Normoweight: 18.0-24.9 kg/m2 and non smokers - Obese =30.0 kg/m2 and non smokers - Smokers: Normoweight and smoke at least 10 cigarettes per day Exclusion Criteria: - Overweight=25.0-29.9 kg/m2 - Patients with Intrauterine device in the last 3 months - Patients who had had hormonal contraceptives in the 2 previous months. - Adnexal or uterine pathologies - Polycystic ovary - Existence of serious or uncontrolled bacterial, fungal or viral infections that could interfere with the involvement of the patient in the study or in the evaluation of the study results. - Any disease or medical condition that could be unstable or could endanger the security of the patient and her compliance in the study. |
Observational Model: Cohort, Time Perspective: Prospective
| Country | Name | City | State |
|---|---|---|---|
| Spain | IVI Valencia | Valencia |
| Lead Sponsor | Collaborator |
|---|---|
| Igenomix |
Spain,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Understanding of the epigenetic and transcriptomic mechanisms that regulate the FOAD | The main objective of the present project is focused on understanding the epigenetic and transcriptomic mechanisms that regulate the fetal origin of adult diseases (FOAD) either by the presence of metabolic disorders in mothers such as obesity, or by the exposure to certain pollutants such as tobacco | 40 months | No |
| Secondary | Analysis of the miRNA expression pattern in the endometrial fluid (EF) in obese patients Analysis of the miRNA expression profile in the endometrial fluid | miRNA expression profile will be analysed in obese women , in comparison to normoweight women during the window of implantation. In turn, the normalization of this particular transcriptomic signature will be studied after the existence of a substantial loss of weight by the patients involved in the study. | 13 months | No |
| Secondary | Analysis of the miRNA expression pattern in the endometrial fluid (EF) in smoker patients | A comparison between the miRNA expression profiles in smoker women vs. non-smoker will be done in the endometrial fluid (EF) during the window of implantation. As in the previous case, it will be studied if that particular pattern is normalized after giving up smoking. | 13 months | No |
| Secondary | Functional analysis | The target genes and the metabolic routes affected by the miRNA profile secreted in both pathological conditions will be defined. | 13 months | No |